Cargando…

Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent

Rapid advances in diagnostic technologies used to detect autoantibodies have made it difficult for even the most modern laboratory to keep abreast of the changing approaches and platforms, not to mention the clinicians who are hard pressed to keep abreast of evolving diagnostic paradigms attended by...

Descripción completa

Detalles Bibliográficos
Autor principal: Fritzler, Marvin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389070/
https://www.ncbi.nlm.nih.gov/pubmed/26000127
http://dx.doi.org/10.1007/s13317-012-0030-7
_version_ 1782365481456369664
author Fritzler, Marvin J.
author_facet Fritzler, Marvin J.
author_sort Fritzler, Marvin J.
collection PubMed
description Rapid advances in diagnostic technologies used to detect autoantibodies have made it difficult for even the most modern laboratory to keep abreast of the changing approaches and platforms, not to mention the clinicians who are hard pressed to keep abreast of evolving diagnostic paradigms attended by these newer techniques. While autoantibody testing is traditionally considered to be primarily serving the realm of diagnostic medicine, there is little doubt that autoantibodies are also being recognized as an approach to providing prognostic and therapeutic information. Accordingly, along with related proteomics, genomics and metabolomics, it is taking on increasing importance in the realm of personalized medicine. In today’s world of autoantibody diagnostics, overarching concerns about false-negative and false-positive autoantibodies tests cannot be summarily dismissed by citing pros or cons of any one technology or diagnostic platform, but often point to persisting gaps in our knowledge about, and understanding of, the origin and roles of autoantibodies. Before we can hope to completely understand the enigmas that attend the results of autoantibody diagnostic tests, perhaps it is time to step back and re-examine long-accepted paradigms and beliefs. This review will address some of the issues that impact on autoantibody detection technologies and some of the considerations and issues that will attend a new orthodoxy of autoantibody diagnostics. These issues will be addressed in the context of “bad” (pathogenic), “good” (protective) or “indifferent” (no apparent role in disease) autoantibodies.
format Online
Article
Text
id pubmed-4389070
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-43890702015-05-21 Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent Fritzler, Marvin J. Auto Immun Highlights Review Article Rapid advances in diagnostic technologies used to detect autoantibodies have made it difficult for even the most modern laboratory to keep abreast of the changing approaches and platforms, not to mention the clinicians who are hard pressed to keep abreast of evolving diagnostic paradigms attended by these newer techniques. While autoantibody testing is traditionally considered to be primarily serving the realm of diagnostic medicine, there is little doubt that autoantibodies are also being recognized as an approach to providing prognostic and therapeutic information. Accordingly, along with related proteomics, genomics and metabolomics, it is taking on increasing importance in the realm of personalized medicine. In today’s world of autoantibody diagnostics, overarching concerns about false-negative and false-positive autoantibodies tests cannot be summarily dismissed by citing pros or cons of any one technology or diagnostic platform, but often point to persisting gaps in our knowledge about, and understanding of, the origin and roles of autoantibodies. Before we can hope to completely understand the enigmas that attend the results of autoantibody diagnostic tests, perhaps it is time to step back and re-examine long-accepted paradigms and beliefs. This review will address some of the issues that impact on autoantibody detection technologies and some of the considerations and issues that will attend a new orthodoxy of autoantibody diagnostics. These issues will be addressed in the context of “bad” (pathogenic), “good” (protective) or “indifferent” (no apparent role in disease) autoantibodies. Springer International Publishing 2012-03-21 /pmc/articles/PMC4389070/ /pubmed/26000127 http://dx.doi.org/10.1007/s13317-012-0030-7 Text en © Springer-Verlag 2012
spellingShingle Review Article
Fritzler, Marvin J.
Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent
title Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent
title_full Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent
title_fullStr Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent
title_full_unstemmed Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent
title_short Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent
title_sort toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389070/
https://www.ncbi.nlm.nih.gov/pubmed/26000127
http://dx.doi.org/10.1007/s13317-012-0030-7
work_keys_str_mv AT fritzlermarvinj towardanewautoantibodydiagnosticorthodoxyunderstandingthebadgoodandindifferent